10.1
Published on May 10, 2024
Exhibit 10.1
AMENDMENT NO. 3 TO CONSULTING AGREEMENT
This AMENDMENT NO. 3 (“Amendment
No. 3”) to the CONSULTING AGREEMENT dated April 1, 2022, as amended on September 19, 2022, (the “Agreement”) between Ocuphire Pharma, Inc., a Delaware corporation having its principal place of business
at 37000 Grand River Avenue, Suite 120, Farmington Hills, Michigan 48335 (the “Company”), and Jay S. Pepose, M.D., having an address at 1815 Clarkson Road, Chesterfield, MO 63017 (“Consultant”) is made as of January 1, 2024 (the “Effective Date”).
I. The term of the
Agreement shall be extended to March 31, 2024.
II. The monthly retainer for March 2024 will be $49,000 which is a one-time increase comprised of the standard $25,000 monthly retainer and additional consulting hours at an hourly rate.
All other terms of the Agreement shall remain in effect without change.
Having understood and agreed to the foregoing, the Company and Consultant have signed this Amendment No. 3 and the same shall be effective
as of the Effective Date.
|
CONSULTANT: |
|
THE COMPANY: |
|||
|
|
|
|
|
|
|
|
|
|
|
Ocuphire Pharma, Inc.
|
||
|
|
|
|
|
|
|
| By: |
/s/ Jay S. Pepose, M.D.
|
|
By: |
/s/ Bernhard Hoffmann
|
|
| Jay S. Pepose, M.D. |
|
Bernhard Hoffmann |
|
||
|
|
4/2/2024
|
|
SVP - Corporate Development |
|
|
|
|
|
|
|
4/2/2024
|
|